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In 2017, the World Health Organization (WHO) published guidelines for the management of advanced human immunodeficiency 
virus (HIV) disease within a public health approach. Recent data suggest that more than a third of people starting antiretroviral 
therapy (ART) do so with advanced HIV disease, and an increasing number of patients re-present to care at an advanced stage of 
HIV disease following a period of disengagement from care. These guidelines recommend a standardized package of care for adults, 
adolescents, and children, based on the leading causes of morbidity and mortality: tuberculosis, severe bacterial infections, crypto-
coccal meningitis, toxoplasmosis, and Pneumocystis jirovecii pneumonia. A package of targeted interventions to reduce mortality 
and morbidity was recommended, based on results of 2 recent randomized trials that both showed a mortality reduction associated 
with delivery of a simplified intervention package. Taking these results and existing recommendations into consideration, WHO 
recommends that a package of care be offered to those presenting with advanced HIV disease; depending on age and CD4 cell count, 
the package may include opportunistic infection screening and prophylaxis, including fluconazole preemptive therapy for those who 
are cryptococcal antigen positive and without evidence of meningitis. Rapid ART initiation and intensified adherence interventions 
should also be proposed to everyone presenting with advanced HIV disease.
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The annual number of people dying from AIDS-related 
causes has declined by 48% since 2003, with 1 million AIDS-
related deaths reported in 2016 [1]. This decline is largely the 
result of expanded access to human immunodeficiency virus 
(HIV) testing and antiretroviral therapy (ART) and an evo-
lution toward treating people earlier in the course of HIV 
infection.[2]
Notwithstanding this progress, the decline in AIDS-related 
deaths appears to have plateaued in recent years. This is largely 
due to the persistent challenge of advanced HIV disease. People 
presenting with advanced HIV disease—defined by the World 
Health Organization (WHO) as having a CD4 cell count <200 
cells/µL or stage III or IV disease; all children <5 years with HIV 
are considered to have advanced HIV disease [3]—are at high 
risk of opportunistic disease and death, even after starting ART, 
with the risk increasing with decreasing CD4 cell count [4, 5]. 
In a recent study from Kenya, Malawi, Uganda, and Zimbabwe, 
almost half of the people with CD4 count <100 cells/µL were clas-
sified as having WHO clinical stage 1 or 2 disease. Hence, iden-
tifying people with advanced HIV disease who are eligible for 
elements of a package of care requires CD4 cell count testing [6].
Recent data from South Africa show that more than a 
third of people starting ART do so with advanced HIV dis-
ease [7]—a trend also observed in many other countries in 
low-, middle-, and high-income settings [8]. In addition, 
there is a growing realization that an increasing propor-
tion of people with advanced HIV disease is represented by 
patients who had previously engaged with the health system 
and started ART, and subsequently disengaged from care. 
Finally, there are those who experience ART failure without 
disengagement [9, 10].
In 2017 WHO convened an expert group to review the evi-
dence and formulate recommendations for the management 
of advanced HIV disease. The objective of these guidelines is to 
define a package of evidence-informed interventions that can be 
provided to people with advanced HIV disease as part of a public 
health approach to managing HIV infection. While the focus of 
the WHO guidelines is on countries with limited resources and 
the greatest burden of disease, the recommendations are intended 
to apply to all settings where advanced HIV disease continues to 
be an important challenge. The elements of the core package are 
summarized in Table 1.
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PRIORITIES FOR THE MANAGEMENT OF ADVANCED 
HIV DISEASE
Leading causes of mortality among adults with advanced 
HIV disease globally include tuberculosis (TB), severe bac-
terial infections, cryptococcal meningitis, toxoplasmosis, and 
Pneumocystis jirovecii pneumonia (PCP) [5, 11, 12].
Two randomized clinical trials have been carried out to assess 
the effectiveness of a package of interventions aimed at reduc-
ing mortality and morbidity among people with advanced HIV 
disease [6, 13].
The first trial (REMSTART), conducted in the United 
Republic of Tanzania and Zambia, randomized 1999 ART-naive 
adults living with HIV with CD4 count <200 cells/µL to receive 
enhanced clinic-based care with a point-of-care serum crypto-
coccal antigen (CrAg) screening and preemptive antifungal 
treatment for those who tested CrAg positive and additional 
community support compared with standard care. In this trial, 
the combination of 4 short home or community visits by lay 
workers combined with CrAg screening followed by treatment 
for cryptococcal antigenemia led to a 28% (95% confidence 
interval [CI], 10%–43%) reduction in mortality among people 
presenting with advanced HIV disease (mortality was 13% in 
the intervention group vs 18% in the group receiving standard 
care; P =  .004), and a decreased rate of hospitalization. A ten-
dency toward improved ART adherence in the intervention 
group compared with the standard-of-care group was reported 
at 6 months, but no difference was noted by 12 months on ART 
[13]. No formal economic evaluation has yet been conducted, 
but a microcosting study found that the enhanced package rep-
resented a 55% increase in the mean cost of care over the first 
3 months, falling to 25% over 1 year of follow-up [14].
The second trial (REALITY) enrolled 1805 participants 
(mainly adults) living with HIV with CD4 counts <100 cells/µL 
(median CD4 count was 36 cells/µL and half were classified as 
WHO clinical stage 1 or 2) from Kenya, Malawi, Uganda, and 
Zimbabwe. Trial participants were randomized to the standard 
of care (cotrimoxazole) according to national guidelines or an 
enhanced prophylaxis package (12 weeks of fluconazole [100 mg 
once daily], 12 weeks of a fixed-dose combination of cotrimoxa-
zole [800 + 160 mg] + isoniazid [300 mg] + pyridoxine [25 mg] 
as a scored once-daily tablet, 5 days of 500 mg of azithromycin 
once daily, and a single dose of 400  mg of albendazole). The 
doses were halved for children 5–12 years old (except for alben-
dazole). All drugs were started simultaneously in the absence of 
any blood tests, and ART was offered on the same day as the 
prophylaxis package. Isoniazid + pyridoxine use beyond 12 
weeks followed national guidelines. Participants already receiv-
ing or needing antimicrobial treatment or prophylaxis pragmat-
ically received it outside the randomized design, and received 
other prophylaxis according to randomization. Patients who had 
started the enhanced-prophylaxis package at the time of ART 
initiation had a 27% lower rate of death than those who received 
Table 1. Components of the Package of Care for People With Advanced Human Immunodeficiency Virus Disease
Intervention Area Intervention CD4 Cell Count
Adults and 
Adolescents Children
Screening and diagnosis Sputum Xpert MTB/RIF assay as first test 
for TB diagnosis in symptomatic patients
Any Yes Yes
Urine LF-LAM for TB diagnosis in patients 
with symptoms and signs of TB
≤100 cells/µL or at any CD4 cell count value if seri-
ously ill
Yes Yesa
CrAg screening <100 cells/µLb Yes No
Prophylaxis and pre-
emptive treatment
Cotrimoxazole prophylaxisc ≤350 cells/µL or WHO clinical stage 3 or 4 event. 
Any CD4 cell count value in settings with high 
prevalence of malaria and/or severe bacterial 
infections
Yes Yesd
TB preventive treatmentb Any Yes Yese
Fluconazole preemptive therapy for CrAg- 
positive patients without evidence of 
meningitis
<100 cells/µL Yes Not applicable 
(screening 
not advised)
ART initiation Rapid ART initiation Any Yes Yes
Defer ART initiation if clinical signs and 





Tailored counseling to ensure optimal adher-
ence to advance disease care package, 
including home visits if feasible
< 200 cells/µL Yes Yes
Abbreviations: ART, antiretroviral therapy; CrAg, cryptococcal antigen; LF-LAM, lateral flow lipoarabinomannan assay; TB, tuberculosis; WHO, World Health Organization.
aLimited data available for children.
bThis threshold was revised upward in 2018 to include people with CD4 <200 cells/µL.
cCotrimoxazole, isoniazid, and pyridoxine are available as a fixed-dose combination tablet.
dPriority should be given to all children <5 years old regardless of CD4 cell count or clinical stage, and those with severe or advanced human immunodeficiency virus clinical disease (WHO 
clinical stage 3 or 4 event and /or those with CD4 ≤350 cells/µL).
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standard prophylaxis with cotrimoxazole alone (8.9% vs 12.2%; 
hazard ratio, 0.73 [95% CI, .55–.98]; P = .03). Incidence of TB was 
significantly lower with enhanced prophylaxis than with stand-
ard prophylaxis (7.1% vs 10.2%. respectively), as was the inci-
dence of cryptococcal disease (1.0% vs 2.6%), candidiasis (1.1% 
vs 2.6%), and new hospitalization (17.0% vs 20.7%) [6]. In the 
main trial report, it was concluded that the REALITY package 
would fall within cost-effectiveness thresholds for low-income 
countries [6]. More extensive costing analyses are under way.
Based on the results of these 2 trials, the WHO Guideline 
Development Group (GDG) for advanced HIV disease recom-
mended providing a package of targeted interventions to re-
duce mortality and morbidity among people presenting with 
advanced HIV disease.
During the GDG meeting, concern was expressed about the 
available evidence to support the specific interventions assessed 
in the trials to be considered for the package. Although severe 
bacterial infections are recognized as a common and frequently 
overlooked cause of HIV-associated morbidity and mortality, the 
GDG did not consider that there is currently enough evidence to 
recommend including an additional broad-spectrum antibiotic 
(azithromycin in addition to cotrimoxazole) within the pack-
age and that the unclear benefits of this specific component of 
the REALITY package (mortality reduction could not clearly 
be attributed to a decline in bacterial infections) do not out-
weigh concerns about the potential for antimicrobial resistance 
development; financial and supply chain considerations were 
also taken into consideration. With respect to use of primary 
fluconazole prophylaxis for preventing cryptococcal disease in 
people presenting with advanced HIV disease, it was recognized 
that in settings where cryptococcal screening tests are not avail-
able or results will be delayed, fluconazole prophylaxis may offer 
programmatic benefits after ruling out pregnancy, with a proven 
reduction in mortality and the incidence of cryptococcal disease.
Taking this into consideration, WHO strongly recommends 
that a package of care be offered to those presenting with 
advanced HIV disease; depending on age and CD4 cell count, 
the package may include opportunistic infection screening and 
prophylaxis, including fluconazole preemptive therapy for those 
who are CrAg positive and without evidence of meningitis, TB 
symptom screen, diagnostic workup, treatment when appro-
priate, and TB preventive therapy in those without TB symp-
toms. Finally, rapid ART initiation and intensified adherence 
interventions should also be proposed to everyone presenting 
with advanced HIV disease [3] (Table 1). 
WHO CAN OFFER THE PACKAGE OF CARE FOR 
ADVANCED HIV DISEASE?
Task sharing may be considered both for performing the point-
of-care diagnostics within the package and for clinical man-
agement. A  good practice statement within the 2016 WHO 
consolidated antiretroviral guidelines states that trained and 
supervised nonlaboratory staff, including lay people, can under-
take blood finger-prick for testing and sample collection [15]. 
Lay workers have successfully delivered CrAg testing [16] and 
point-of-care CD4 cell count [17], and this approach should be 
considered as a way to improve access to essential diagnostics 
for the management of advanced HIV disease at peripheral sites. 
Task sharing to nurses and other midlevel health workers for 
the clinical management of people with advanced HIV should 
be supported with training and mentorship. Initial screening 
procedures, treatment of TB and some opportunistic infections, 
and prophylaxis may all be provided within a well-supported, 
nurse-led program. However, clear referral criteria and care 
pathways must be in place to ensure appropriate investigation 
and higher-level clinical management when required. Where 
referral is not feasible, lower-level health workers should con-
sider presumptive treatment based on the clinical presentation, 
ideally after consulting with an experienced clinician.
INTENSITY OF FOLLOW-UP FOR PEOPLE WITH 
ADVANCED HIV DISEASE
People with advanced HIV disease require closer follow-up 
during the initial period of receiving ART to monitor the re-
sponse to ART and to identify signs and symptoms of possible 
immune reconstitution inflammatory syndrome. During the 
REMSTART study, weekly home visits were provided during the 
first month on ART [13]. Even with close initial follow-up in 
the REALITY trial, many people died at home, with most deaths 
occurring very soon after ART initiation. People discharged 
after hospitalization for advanced HIV disease may also require 
more intensive follow-up. The feasibility of more frequent visits 
is context specific and may also depend on the person’s ability to 
travel to the clinical site. People missing appointments should 
also be rapidly traced by phone or through home visits. Where 
face-to-face contact is not feasible, distance contact (through, 
eg, telephone consultation, mobile health, text messaging) or 
visits by a community health worker or home-based caregiver 
should be considered, with consent of the client. For hospitalized 
patients, programs should provide measures to improve linkage 
and follow-up after discharge such as outpatient primary care 
clinic visits and home visits by community health workers to re-
duce the risks of loss to follow-up and mortality after discharge.
CONSIDERATIONS FOR SPECIFIC POPULATIONS
The advanced disease package is based on evidence from tri-
als conducted in ART-naive, mainly adult patients in southern 
Africa.
For children, the major causes of mortality and morbidity among 
those with advanced HIV disease are TB, severe bacterial infec-
tions, and PCP but, in contrast with adults, cryptococcal disease 
is relatively rare. For this reason, extrapolation from adult studies 
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components of the package of care for young children and optimal 
administration and delivery in this age group [18].
For ART-experienced patients with advanced HIV who have 
disengaged from care and then return or are failing their cur-
rent regimen, the key questions relate to choice of ART regimen 
and timing of any switch. Restarting ART rapidly is of utmost 
importance, except in the presence of cryptococcal or tubercu-
losis meningitis. If ART interruption was complete (due, eg, to 
some travel duties or migration), restarting the first-line ART is 
possible. If partial ART exposure is suspected or the patient is 
severely ill, an expedited switch to a new regimen when needed 
should be facilitated by reducing the time between the first and 
second viral load test (1–3  months) and by paying increased 
attention to ensuring rapid turnaround and action on the 
results. Where rapid viral load testing is not available, the de-
cision to switch should be assessed according to the individual 
clinical presentation and adherence history of the patient [19].
Finally, there are important regional differences with re-
spect to coinfections. Fungal infections, notably histoplas-
mosis and talaromycosis, are associated with advanced HIV 
disease in specific geographical areas. In some high-income 
countries, advanced liver disease secondary to hepatitis B 
and C is among the leading infectious causes of mortality. 
The advanced HIV disease package should therefore take 
into account the need for adapting interventions according 
to local epidemiology.
RESEARCH PRIORITIES
The WHO guideline development process offers an opportu-
nity to identify priority areas for future research [20]. These are 
summarized in Table 2. Research priorities related to diagnostics 
include the need for a simplified tool to perform CD4 cell count 
testing to ensure that people with advanced immune disease 
are identified. Ongoing research is being undertaken, including 
using a semiquantitative CD4 cell count lateral flow assay for 
which operational research will be required to evaluate perfor-
mance and feasibility under field conditions. Further research 
is also needed to develop simplified point-of-care diagnostics, 
including for TB and nontuberculous mycobacterial diseases, 
severe bacterial infections, PCP, toxoplasmosis, cytomegalovirus 
disease, and other opportunistic infections specific to geographi-
cal regions, such as histoplasmosis and talaromycosis. Enhanced 
TB screening with Xpert MTB/RIF assay, regardless of symp-
toms, was provided in both groups in the REMSTART study [13] 
and its impact could therefore not be assessed. Further studies 
are needed to assess improved strategies for TB screening and 
clarify the role of presumptive TB treatment.
Other research priorities include defining the optimal package of 
prophylactic interventions for people with advanced HIV disease, 
the optimal preemptive treatment strategy for people identified as 
CrAg positive at screening, and benefits and risks of routine use of 
broad-spectrum antibiotic therapy (in addition to cotrimoxazole) 
within a public health approach, and specifically, the independent 
effect of short-course azithromycin on mortality. The GDG also 
highlighted programmatic assessment of the intensity of follow-up 
required and adherence strategies for people with advanced HIV 
disease as important areas for implementation research.
To date, trials have only examined the benefits of an inter-
vention package among those presenting for ART care without 
previous ART exposure. The optimal management approach for 
people re-presenting for care with advanced HIV disease after 
treatment interruption warrants further investigation. Data to 
support the effectiveness and safety  of intervention packages 
in routine care settings would also be of value. In addition, as 
these trials have not investigated the benefit of an intervention 
package for infants and children <5 years of age, specific com-
ponents and optimal delivery in this population warrant fur-
ther research. Finally, region-specific packages of care should be 
defined and their effectiveness assessed.
Table 2. Research Priorities
Intervention Area Priority
General • Effectiveness of the package of care for ART-experienced patients
•  Defining the optimal package of care for children
Diagnosis •  Simplified tool to perform CD4 cell count testing
•  Point-of-care diagnostics for TB and nontuberculous mycobacteria, severe bacterial infections, Pneumocystis jirovecii pneumonia, 
toxoplasmosis, cytomegalovirus disease
•  Strategies to improve TB screening
•  Approaches to improve accessibility of brain imaging
Prophylaxis •  Optimal package of prophylactic interventions for people who have not yet started ART and those returning to care after 
interruption
•  Role of routine fluconazole prophylaxis vs CrAg screening and preemptive treatment of CrAg-positive patients in operational 
settings
•  Role of additional antibiotic prophylaxis for severe bacterial infections
Treatment •  Monitoring and switching strategies for patients representing and restating ART after a period of disengagement from care
•  Simple tests to assess ART adherence
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CONCLUSIONS
Continued progress in improving access to HIV diagnosis and 
treatment remains at the core of the global response toward 
achieving the target of ending AIDS as a public health threat 
and providing universal health coverage. Nevertheless, HIV 
infection remains a leading cause of illness and death in many 
countries, particularly in sub-Saharan Africa, and evidence to 
date suggests that responding to advanced HIV disease will 
remain an important public health priority for several years to 
come. National HIV programs are encouraged to implement 
the package of interventions recommended by WHO, and 
WHO will update this package according to new evidence and 
implementation experience.
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